The manufacturer&rsquo.

The FDA has approved 2 Novartis inhalation powders for the treatment of chronic obstructive pulmonary disease . The manufacturer’s indacaterol/glycopyrrolate inhalation powder is indicated for the long-term maintenance treatment of COPD, even though its glycopyrrolate inhalation powder is approved for use as a stand-alone COPD monotherapy. Both medications are delivered via the low-resistance Neohaler inhaler, permitting them to become more easily administered by patients with different severities of airflow limitation få mer informasjon . The approval of Utibron Neohaler was based on data from phase 3 studies in which the drug’s efficacy and safety were examined in a complete of 2654 patients with COPD.

Improving communications is a goal of follow-up study from U-M’s Cancer Surveillance and Outcomes Research Team, the experts who conducted this research.. 19 % of breast cancer patients don’t receive recommended radiation after mastectomy One-5th of women who should receive radiation following a mastectomy are not getting this potentially lifesaving treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. The scholarly study looked at 396 women who were treated with a mastectomy for breast cancer. The researchers found that 19 % of females who fell obviously within recommendations recommending radiation treatment following the mastectomy didn’t receive that treatment. Results of the analysis appear on-line in the journal Tumor and will be published in the March 15 issue.